Roche has announce the launch of the Elecsys Troponin T high-sensitive (TnT hs) assay for use on cobas and MODULAR Analytics serum work areas in the UK and Ireland. This highly sensitive diagnostic assay has been developed to improve the detection and exclusion of myocardial injury in the early stages, demonstrating excellent precision in the range 0.003–10 ng/mL troponin T in serum or plasma, and to help identify risk of future coronary events.
Elecsys TnT hs is the only commercially available assay that not only meets the precision requirements (<10% coefficient of variation at the 99th percentile of the reference range) but also demonstrates the best level of assay designation (95% measurable normal values below the 99th percentile). In addition, in a recent comparative evaluation, Elecsys TnT hs displayed the highest sensitivity (95 %) and negative predictive value (99%) in the diagnosis of unstable angina at presentation. This excellent sensitivity and precision make the Elecsys TnT hs assay a valuable and much needed tool for the early detection and exclusion of acute myocardial infarction.
The robustness of the Elecsys TnT hs assay against interfering factors
ensures high result accuracy and consistency in patient follow-up, and the
availability of a STAT (nine minute) version for rapid results delivers unrivalled turnaround time for emergency samples.
www.roche.com